the second trimester in 60% of the patients in whom the fetuses went on to experience intrauterine growth retardation without the occurrence of maternal pre-eclampsia, and also in 62% of the patients who went on to have normal courses of pregnancy. The same group of researchers also reported that, although AT1-AA was also detected in pregnant women with second-trimester abnormality in uterine perfusion but who did not go on to develop any pathology of pregnancy, sFlt1 levels in this category of patients were not significantly elevated as compared to those with normal uterine perfusion. Additionally, although women with abnormal perfusion who went on to develop a pathology in later pregnancy had AT1-AA values similar to those who went on to have normal pregnancy courses, their sFlt1 levels were significantly higher. However, AT1-AA and sFlt1 levels were not correlated.
Maynard et al. 3 demonstrated that administration of sFlt1 to pregnant SpragueDawley rats induced hypertension, heavy proteinuria, and a dose-dependent, characteristic renal lesion; however, these authors reported that they could not distinguish from their study whether sFlt1 production by the placenta was a primary event in the disease process.
As in humans with this disease condition, the first event in the reduced uterine perfusion pressure (RUPP) rat model of pre-eclampsia is uteroplacental ischemia. The systemic hemodynamic and uteroplacental blood flow alterations are very similar to those observed in women with pre-eclampsia. 4 In this RUPP model of pregnant rats, hypoxia induces a decrease in innate antioxidant activity and an increase in oxidative product formation. Both tumor necrosis factor-α and IL-6 were found to be elevated as a response to chronic reduction in uterine perfusion, and this increase correlated to a rise in arterial pressure and a reduction in renal function. Finally, in the RUPP model, the ratios of sFlt1/placental growth factor and sFlt1/vascular endothelial growth factor increase in the maternal circulation and mimic the imbalance observed in women with pre-eclampsia; 2 however, this imbalance appears only as a secondary abnormality, after uteroplacental ischemia and oxidative stress. For these reasons, the conclusions arrived at by Parrish et al. in their study cited above regarding the causative correlation between elevated AT1-AA values and pre-eclampsia is questionable.
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